Physician profile
Jonathan D Cyphers
NPI 1134364813
$13,358.76
in general payments reported to CMS, 2019-2025
21 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609 · 2022: $1,895 · 2023: $4,028 · 2024: $3,601 · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,790 · Consulting Fee: $700 · Education: $300 · Travel and Lodging: $64.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,789.73 |
| Consulting Fee | $700.00 |
| Education | $300.36 |
| Travel and Lodging | $64.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,504.10 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $2,266.53 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,473.58 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $1,011.16 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $649.01 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $586.78 | 2021-2025 | Otezla, Otezla |
| Organon LLC | $570.58 | 2023-2025 | Hadlima, Vtama, Nexplanon |
| Pfizer INC. | $565.51 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $558.51 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $501.02 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $437.02 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Lilly USA, LLC | $396.51 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $370.88 | 2022-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $363.95 | 2023-2025 | Zoryve |
| Genzyme Corporation | $359.79 | 2021-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $312.45 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $199.98 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Leo Pharma INC. | $81.73 | 2022-2023 | Adbry |
| Genentech USA, INC. | $68.51 | 2023-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.79 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cyphers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.